Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Biowaiver monographs for immediate release solid oral dosage forms: pyrazinamide.

Authors
  • Becker, C
  • Dressman, J B
  • Amidon, G L
  • Junginger, H E
  • Kopp, S
  • Midha, K K
  • Shah, V P
  • Stavchansky, S
  • Barends, D M
Type
Published Article
Journal
Journal of Pharmaceutical Sciences
Publisher
Elsevier
Publication Date
Sep 01, 2008
Volume
97
Issue
9
Pages
3709–3720
Identifiers
DOI: 10.1002/jps.21250
PMID: 18271031
Source
Medline
License
Unknown

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing pyrazinamide as the only active pharmaceutical ingredient (API) are reviewed. Pyrazinamide is BCS Class III, with linear absorption over a wide dosing range. The risk of bioinequivalence is estimated to be low. Depending on the definition used, pyrazinamide can be classified as a narrow therapeutic index (NTI) drug, which is usually a caveat to biowaiving but may be deemed acceptable if the Summary of Product Characteristics (SmPCs) of the test product stipulates the need for regular monitoring of liver function. It is concluded that a biowaiver can be recommended for IR solid oral dosage only when the test product (a) contains only excipients present in pyrazinamide IR solid oral drug products approved in ICH or associated countries, (b) these excipients are present in amounts normally used in IR solid oral dosage forms, (c) the test product is very rapidly dissolving, (d) the SmPC of the test product indicates the need for monitoring of the patient's liver function.

Report this publication

Statistics

Seen <100 times